NOTES TO THE CONSOLIDATED FINANCIALSTATEMENTS Continued 6.
PROFIT FOR THE YEAR Continued The Groups auditors remuneration on a worldwide basis was as below: 2012 2011 $000 $000 Audit of the Companys annual accounts 387 324 Audit of the Companys subsidiaries pursuant to legislation 815 825 Total audit fees 1,202 1,149 Audit related services 128 463 Total audit and audit related fees 1,330 1,612 Tax compliance services 91 135 Tax advisory services 266 239 Other services 254 1,748 Total non-audit fees 611 2,122 Total fees 1,941 3,734 Audit related services relate to review procedures in respect of the interim financial information.
The prior year gure includes services for the opening balance sheet work inrespect of MSI, Promopharm and the prospectus work relating to the Promopharm acquisition.
Other services include transaction services related to corporate transactions.
The previous years gure includes integration planning performed in the US in respect oftheMSIacquisition.
A description of the work of the Audit Committee is set out in the Audit Committee report on pages 72 to 75 and includes an explanation ofhowauditor objectivity and independence is safeguarded when non-audit services are provided by the auditor.
STAFF COSTS The average monthly number of employees including Executive Directors was: 2012 2011 Number Number Production 3,716 3,625 Sales and marketing 1,986 1,699 Research and development 285 239 General and administrative 662 602 6,649 6,165 2012 2011 $000 $000 Their aggregate remuneration comprised: Wages, salaries and bonuses 210,195 175,627 Social security costs 17,938 15,051 Post-employment benefits 5,911 3,559 End of service indemnity 5,585 2,934 Share-based payments 7,961 7,507 Car and housing allowance 14,579 13,483 Other costs and employee benefits 32,019 19,678 294,188 237,839 132 HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2012
